Table 2. List of 24 antitumor agents examined by using sarcoma cell line panel.
| Agents | Mode of action | Manufacturer |
|---|---|---|
| Molecularly targeted agents | ||
| ZSTK474 | Pan-PI3K inhibitor | Zenyaku Kogyo Co., Ltd. |
| buparlisib (BKM120) | Pan-PI3K inhibitor | Novartis International AG |
| pictilisib (GDC-0941) | Pan-PI3K inhibitor | Genentech inc. |
| alpelisib (BYL719) | PI3K-alpha specific inhibitor | Novartis International AG |
| ZSTK534 | Metabolites of ZSTK474 | Zenyaku Kogyo Co., Ltd. |
| ZSTK778 | ||
| ZSTK1741 | ||
| ZSTK2209 | ||
| linsitinib (OSI906) | IGF-1R inhibitor | OSI Pharmaceuticals, Inc. |
| everolimus (RAD-001) | mTOR inhibitor | Novartis International AG |
| selumetinib (AZD6244) | MEK1/2 inhibitor | AstraZeneca plc. |
| vemurafenib | BRAF (V600E) inhibitor | Genentech inc. |
| gefitinib | EGFR inhibitor | AstraZeneca plc. |
| sorafenib | Multikinase inhibitor | Bayer AG & Onyx Pharmaceuticals Inc. |
| pazopanib | Angiogenesis (multi-kinase inhibitor) | Novartis International AG |
| imatinib | Bcr-Abl inhibitor | Novartis International AG |
| sunitinib | Multikinase inhibitor | Pfizer Inc. |
| bortezomib | Proteasome inhibitor | The Takeda Oncology Company (Millennium Pharmaceuticals, Inc.) |
| Chemotherapy agents | ||
| doxorubicin | Antineoplastic antibiotics | Kyowa Hakko Kirin Co., Ltd. |
| docetaxel | Microtubule depolymerization | Sanofi S. A. |
| gemcitabine | Cytosine analogue | Eli Lilly and Company |
| cisplatin | DNA cross-linker | Bristol-Myers Squibb Co. |
| carboplatin | DNA cross-linker | Bristol-Myers Squibb Co. |
| ifosfamide | DNA alkylator | Baxter International Inc. etc. |